Equity Profile

VERA

Vera Therapeutics, Inc.

Health CareBiotechnology$2.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.59

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases. Operating in the health care sector, Vera is working to address unmet medical needs, which is increasingly important as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q1-2026, Vera reported an EPS of -1.69, which was significantly worse than the expected -1.26, leading to a negative market reaction. The company did not provide revenue figures, leaving investors uncertain about its financial trajectory.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Vera, with a consensus EPS of -1.59. Investors are closely watching for any signs of improvement in the company's financial performance.

Bull Case

If Vera can narrow its losses and provide positive updates on its pipeline, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lack of revenue could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Key Metrics to Watch

EPS

-1.59

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is Vera taking to improve its EPS this quarter?

Given the company's history of missing EPS estimates, any concrete plans for improvement will be critical for investor confidence.

Are there any updates on the development of new therapies that could generate future revenue?

Investors are eager for signs of progress in Vera's pipeline, as this could indicate potential revenue streams and impact the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Vera's potential for a turnaround, as recent developments in its pipeline could lead to unexpected positive results.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility, which could lead to surprises.

Vera's historical performance shows that even with misses, the stock has occasionally reacted positively, suggesting potential for recovery.

Key Risk

If Vera can demonstrate any progress in its therapy developments, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce or challenge investor confidence in Vera's ability to turn around its financial situation.

Bull Confirmed If

An EPS of -1.38 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than -1.73 would confirm the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations, history suggests a potential stock increase of around 3.5%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity on future plans.

Miss

If Vera misses expectations, history suggests a decline of about 2.15%, reinforcing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the development timeline for new therapies.
2Any specific strategies to improve EPS moving forward.
3Insights into potential partnerships or collaborations.
4Management's outlook on market conditions affecting the business.
5Details on cost management strategies to reduce losses.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.59

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Vera, with a consensus EPS of -1.59. Investors are closely watching for any signs of improvement in the company's financial performance.

Bull Case

If Vera can narrow its losses and provide positive updates on its pipeline, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lack of revenue could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Key Metrics to Watch

EPS

-1.59

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is Vera taking to improve its EPS this quarter?

Given the company's history of missing EPS estimates, any concrete plans for improvement will be critical for investor confidence.

Are there any updates on the development of new therapies that could generate future revenue?

Investors are eager for signs of progress in Vera's pipeline, as this could indicate potential revenue streams and impact the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Vera's potential for a turnaround, as recent developments in its pipeline could lead to unexpected positive results.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility, which could lead to surprises.

Vera's historical performance shows that even with misses, the stock has occasionally reacted positively, suggesting potential for recovery.

Key Risk

If Vera can demonstrate any progress in its therapy developments, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce or challenge investor confidence in Vera's ability to turn around its financial situation.

Bull Confirmed If

An EPS of -1.38 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than -1.73 would confirm the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations, history suggests a potential stock increase of around 3.5%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity on future plans.

Miss

If Vera misses expectations, history suggests a decline of about 2.15%, reinforcing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the development timeline for new therapies.
2Any specific strategies to improve EPS moving forward.
3Insights into potential partnerships or collaborations.
4Management's outlook on market conditions affecting the business.
5Details on cost management strategies to reduce losses.